The Technical AnalystExchange: XETRA Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
SynBiotic SE Price, Forecast, Insider, Ratings, Fundamentals & Signals
6.13% €9.70
Europe/Berlin / 2 mai 2024 @ 17:36
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 48.11 mill |
| EPS: | -5.90 |
| P/E: | -1.640 |
| Earnings Date: | Aug 21, 2024 |
| SharesOutstanding: | 4.96 mill |
| Avg Daily Volume: | 0.0655 mill |
| RATING 2024-05-02 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | n/a | n/a | n/a | n/a | n/a | |
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.640 | sector: PE 19.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.04x |
| Company: PE -1.640 | industry: PE 39.15 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€-1.192 (-112.29%) €-10.89 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
€ 7.77 - 11.35 ( +/- 18.77%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €9.70 (6.13% ) |
| Volume | 0.0102 mill |
| Avg. Vol. | 0.0655 mill |
| % of Avg. Vol | 15.51 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SBX.DE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SBX.DE
SynBiotic SE engages in the development of medicines and over-the-counter wellness products based on cannabinoids. It focuses on synthetic production of cannabinoids, drug development, nutritional supplements, and cosmetic products. The company was formerly known as Ledgertech SE and changed its name to Ledgertech SE. SynBiotic SE based in Munich, Germany.